157 related articles for article (PubMed ID: 26907571)
21. HepaCAM‑PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.
He Z; Gao Y; Li T; Yu C; Ou L; Luo C
Int J Oncol; 2022 Apr; 60(4):. PubMed ID: 35191516
[TBL] [Abstract][Full Text] [Related]
22. The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects.
Singh R; Mills IG
Front Oncol; 2021; 11():704353. PubMed ID: 34660272
[TBL] [Abstract][Full Text] [Related]
23. Targeting Mitochondrial Metabolism in Prostate Cancer with Triterpenoids.
Mamouni K; Kallifatidis G; Lokeshwar BL
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671107
[TBL] [Abstract][Full Text] [Related]
24. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics.
Rai A; Noor S; Ahmad SI; Alajmi MF; Hussain A; Abbas H; Hasan GM
Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33494239
[TBL] [Abstract][Full Text] [Related]
26. Methylcrotonoyl-CoA Carboxylase 2 Promotes Proliferation, Migration and Invasion and Inhibits Apoptosis of Prostate Cancer Cells Through Regulating GLUD1-P38 MAPK Signaling Pathway.
He J; Mao Y; Huang W; Li M; Zhang H; Qing Y; Lu S; Xiao H; Li K
Onco Targets Ther; 2020; 13():7317-7327. PubMed ID: 32801758
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial PAK6 inhibits prostate cancer cell apoptosis
Li T; Li Y; Liu T; Hu B; Li J; Liu C; Liu T; Li F
Theranostics; 2020; 10(6):2571-2586. PubMed ID: 32194820
[No Abstract] [Full Text] [Related]
28. LRPPRC: A Multifunctional Protein Involved in Energy Metabolism and Human Disease.
Cui J; Wang L; Ren X; Zhang Y; Zhang H
Front Physiol; 2019; 10():595. PubMed ID: 31178748
[TBL] [Abstract][Full Text] [Related]
29. Transporter and protease mediated delivery of platinum complexes for precision oncology.
Hambley TW
J Biol Inorg Chem; 2019 Jun; 24(4):457-466. PubMed ID: 31093745
[TBL] [Abstract][Full Text] [Related]
30. Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.
Gómez-Cebrián N; Rojas-Benedicto A; Albors-Vaquer A; López-Guerrero JA; Pineda-Lucena A; Puchades-Carrasco L
Metabolites; 2019 Mar; 9(3):. PubMed ID: 30857149
[TBL] [Abstract][Full Text] [Related]
31. The Role of Lactate Metabolism in Prostate Cancer Progression and Metastases Revealed by Dual-Agent Hyperpolarized
Bok R; Lee J; Sriram R; Keshari K; Sukumar S; Daneshmandi S; Korenchan DE; Flavell RR; Vigneron DB; Kurhanewicz J; Seth P
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30813322
[TBL] [Abstract][Full Text] [Related]
32. Hyperpolarized
Vishwanath V; Mayer D; Fu D; Wnorowski A; Siddiqui MM
Transl Androl Urol; 2018 Oct; 7(5):855-863. PubMed ID: 30456188
[TBL] [Abstract][Full Text] [Related]
33. Linking cellular metabolism and metabolomics to risk-stratification of prostate cancer clinical aggressiveness and potential therapeutic pathways.
Eidelman E; Tripathi H; Fu DX; Siddiqui MM
Transl Androl Urol; 2018 Sep; 7(Suppl 4):S490-S497. PubMed ID: 30363493
[TBL] [Abstract][Full Text] [Related]
34. The Metabolic Phenotype of Prostate Cancer.
Eidelman E; Twum-Ampofo J; Ansari J; Siddiqui MM
Front Oncol; 2017; 7():131. PubMed ID: 28674679
[TBL] [Abstract][Full Text] [Related]
35. Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges.
Naponelli V; Ramazzina I; Lenzi C; Bettuzzi S; Rizzi F
Antioxidants (Basel); 2017 Apr; 6(2):. PubMed ID: 28379200
[TBL] [Abstract][Full Text] [Related]
36. Metabolic targets for potential prostate cancer therapeutics.
Twum-Ampofo J; Fu DX; Passaniti A; Hussain A; Siddiqui MM
Curr Opin Oncol; 2016 May; 28(3):241-7. PubMed ID: 26907571
[TBL] [Abstract][Full Text] [Related]
37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
38. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.
Costello LC; Franklin RB
Mol Cancer; 2006 May; 5():17. PubMed ID: 16700911
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues.
Singh KK; Desouki MM; Franklin RB; Costello LC
Mol Cancer; 2006 Apr; 5():14. PubMed ID: 16595004
[TBL] [Abstract][Full Text] [Related]
40. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.
Pertega-Gomes N; Felisbino S; Massie CE; Vizcaino JR; Coelho R; Sandi C; Simoes-Sousa S; Jurmeister S; Ramos-Montoya A; Asim M; Tran M; Oliveira E; Lobo da Cunha A; Maximo V; Baltazar F; Neal DE; Fryer LG
J Pathol; 2015 Aug; 236(4):517-30. PubMed ID: 25875424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
